<?xml version="1.0" ?><ns2:com.thomson.ls.soa.stack.soaservices.service.contract.soap.v4.search.SearchOutput xmlns:ns2="local" id="eeeccaba-90b7-4398-96b6-e72625139087" dataset="sourcesCorporatePublication" time="23"><serviceExecutionTime>28</serviceExecutionTime><lastDatasetUpdate>2019-02-16T00:12:36Z</lastDatasetUpdate><PagedResults total="81" firstRow="1" lastRow="81"><Result pos="1"><Field name="sourceId" type="string">1386159</Field><Field name="corporatePublicationTitle" type="string">Insulin SEDICO</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-02-25T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">SEDICO Co</Field></Result><Result pos="2"><Field name="sourceId" type="string">1080209</Field><Field name="corporatePublicationTitle" type="string">Insulin Analogs</Field><Field name="corporatePublicationType" type="string">Company Brochure</Field><Field name="corporatePublicationDatePublication" type="datetime">2010-03-08T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">New England Healthcare Institute</Field></Result><Result pos="3"><Field name="sourceId" type="string">1073331</Field><Field name="corporatePublicationTitle" type="string">Biodel: Pipeline, BIOD- Smart Insulin</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2010-02-05T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Biodel Inc</Field></Result><Result pos="4"><Field name="sourceId" type="string">765924</Field><Field name="corporatePublicationTitle" type="string">Delivery of Biologics - oral insulin</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2007-02-14T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">MediVas LLC</Field></Result><Result pos="5"><Field name="sourceId" type="string">1355810</Field><Field name="corporatePublicationTitle" type="string">Ansulin - Insulin Human (rDNA) USP</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-01-10T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Square Pharmaceuticals Ltd</Field></Result><Result pos="6"><Field name="sourceId" type="string">606214</Field><Field name="corporatePublicationTitle" type="string">Novo Nordisk insulin product overview</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2005-06-08T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Novo Nordisk A/S</Field></Result><Result pos="7"><Field name="sourceId" type="string">492583</Field><Field name="corporatePublicationTitle" type="string">Novo Nordisk US - Insulin</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2003-06-06T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Novo Nordisk A/S</Field></Result><Result pos="8"><Field name="sourceId" type="string">400110</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: insulin glargine</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-02-27T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Aventis SA</Field></Result><Result pos="9"><Field name="sourceId" type="string">372335</Field><Field name="corporatePublicationTitle" type="string">Drug Development Pipeline - AERx (insulin)</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-06-11T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Novo Nordisk A/S</Field></Result><Result pos="10"><Field name="sourceId" type="string">1489984</Field><Field name="corporatePublicationTitle" type="string">Commissioning Support Insulin Degludec (Tresiba)</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-02-28T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Keele University (Midlands Therapeutics Review &amp; Advisory Committee)</Field></Result><Result pos="11"><Field name="sourceId" type="string">662549</Field><Field name="corporatePublicationTitle" type="string">Final Appraisal Determination - Long-acting insulin analogues for the treatment of diabetes – insulin glargine</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-10-18T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE</Field></Result><Result pos="12"><Field name="sourceId" type="string">371716</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: phosphorylated human insulin, Diabecore</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-06-11T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Diabecore Medical Inc</Field></Result><Result pos="13"><Field name="sourceId" type="string">2057870</Field><Field name="corporatePublicationTitle" type="string">Drug Approval Document of SOLIQUA (insulin glargine / lixisenatide)</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2017-07-13T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Health Surveillance Agency</Field></Result><Result pos="14"><Field name="sourceId" type="string">1878395</Field><Field name="corporatePublicationTitle" type="string">Over the counter covered product list (insulin)</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2016-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">MedicareBlue Rx</Field></Result><Result pos="15"><Field name="sourceId" type="string">1215327</Field><Field name="corporatePublicationTitle" type="string">AFREZZA - A Novel Ultra Rapid-Acting Insulin</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2011-08-16T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Mannkind Corp</Field></Result><Result pos="16"><Field name="sourceId" type="string">988483</Field><Field name="corporatePublicationTitle" type="string">Recombinant Human Pro-insulin C Peptide For Injection</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2006-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Newsummit Biopharma Co Ltd</Field></Result><Result pos="17"><Field name="sourceId" type="string">1489875</Field><Field name="corporatePublicationTitle" type="string">Review Afrezza Inhaled Insulin for Diabetes Mellitus</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-06-30T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Canadian Agency for Drugs and Technologies in Health</Field></Result><Result pos="18"><Field name="sourceId" type="string">2061439</Field><Field name="corporatePublicationTitle" type="string">Drug Approval Document of XULTOPHY (liraglutide; insulin degludec)</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2017-03-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Health Surveillance Agency</Field></Result><Result pos="19"><Field name="sourceId" type="string">1490319</Field><Field name="corporatePublicationTitle" type="string">Evidence Summary - ESNM24: Type 1 diabetes: insulin degludec</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-10-22T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Institute for Health and Care Excellence</Field></Result><Result pos="20"><Field name="sourceId" type="string">1080451</Field><Field name="corporatePublicationTitle" type="string">Drug datasheet: Humalog Mix75/25 (75% insulin lispro protamine suspension and 25% insulin lispro injection)</Field><Field name="corporatePublicationType" type="string">Drug Package Insert</Field><Field name="corporatePublicationDatePublication" type="datetime">2010-03-09T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Eli Lilly &amp; Co</Field></Result><Result pos="21"><Field name="sourceId" type="string">1487298</Field><Field name="corporatePublicationTitle" type="string">FDA Endocrinologic and Metabolic Drugs Advisory Committee Meeting - Briefing Document for Insulin Degludec and Insulin Degludec/Aspart</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2012-11-08T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Food and Drug Administration</Field></Result><Result pos="22"><Field name="sourceId" type="string">1726535</Field><Field name="corporatePublicationTitle" type="string">Development of Novel Nanoemulsion for Insulin Oral Administration</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2014-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Innopharmax Inc</Field></Result><Result pos="23"><Field name="sourceId" type="string">1713297</Field><Field name="corporatePublicationTitle" type="string">Summary Basis of Decision for Basaglar (insulin glargine)</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2015-10-21T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Health Canada</Field></Result><Result pos="24"><Field name="sourceId" type="string">452854</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: insulin (oral), Nobex/GlaxoSmithKline</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-05-28T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">GlaxoSmithKline plc</Field></Result><Result pos="25"><Field name="sourceId" type="string">337500</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: insulin (oral), Protein Delivery Inc</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1999-08-23T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Protein Delivery Inc</Field></Result><Result pos="26"><Field name="sourceId" type="string">1892390</Field><Field name="corporatePublicationTitle" type="string">European public assessment report for Lusduna (insulin glargine)</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2017-01-12T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">European Medicines Agency</Field></Result><Result pos="27"><Field name="sourceId" type="string">1765422</Field><Field name="corporatePublicationTitle" type="string">UK launch for new insulin glargine biosimilar Abasaglar</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2015-09-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Diabetes.co.uk</Field></Result><Result pos="28"><Field name="sourceId" type="string">903616</Field><Field name="corporatePublicationTitle" type="string">Product information: Emisphere's oral insulin program</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2008-04-17T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Emisphere Technologies Inc</Field></Result><Result pos="29"><Field name="sourceId" type="string">1075323</Field><Field name="corporatePublicationTitle" type="string">Novo Nordisk is discontinuing several insulin delivery devices</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2010-02-15T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Novo Nordisk A/S</Field></Result><Result pos="30"><Field name="sourceId" type="string">1211351</Field><Field name="corporatePublicationTitle" type="string">Material safety data sheet : Insulin, Human</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2011-08-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Eli Lilly &amp; Co</Field></Result><Result pos="31"><Field name="sourceId" type="string">1490320</Field><Field name="corporatePublicationTitle" type="string">Evidence Summary - ESNM25: Type 2 diabetes: insulin degludec</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-10-22T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Institute for Health and Care Excellence</Field></Result><Result pos="32"><Field name="sourceId" type="string">1080253</Field><Field name="corporatePublicationTitle" type="string">Insulin initiation in type 2 diabetes</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2010-03-08T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Novo Nordisk A/S</Field></Result><Result pos="33"><Field name="sourceId" type="string">1060682</Field><Field name="corporatePublicationTitle" type="string">Early Communication About Safety of Lantus (insulin glargine)</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2009-07-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">FDA</Field></Result><Result pos="34"><Field name="sourceId" type="string">1994271</Field><Field name="corporatePublicationTitle" type="string">Registration of NCEs: RYZODEG 70/30 FLEXTOUCH and RYZODEG 70/30 PENFILL (70% insulin degludec / 30% insulin aspart)</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2017-11-29T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Therapeutic Goods Administration</Field></Result><Result pos="35"><Field name="sourceId" type="string">1075229</Field><Field name="corporatePublicationTitle" type="string">UPDATE: Discontinuation of Humulin 50/50 (50% Human Insulin Isophane Suspension and 50% Human Insulin Injection [rDNA Origin])</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2009-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Eli Lilly &amp; Co</Field></Result><Result pos="36"><Field name="sourceId" type="string">1491250</Field><Field name="corporatePublicationTitle" type="string">Novo Nordisk Briefing Document - FDA Endocrinologic and Metabolic Drug Advisory Committee - Insulin Degludec and Insulin Degludec/Insulin Aspart Treatment to Improve Glycemic Control in Patients with Diabetes Mellitus (NDAs 203314 and 203313)</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2012-11-08T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Food and Drug Administration</Field></Result><Result pos="37"><Field name="sourceId" type="string">1544390</Field><Field name="corporatePublicationTitle" type="string">Better Acceptance of a Single injection Apidra (insulin glulisine) Added to once daily Lantus (insulin glargine) versus twice daily Premixed insulin in a real Life Use Setting (BASAAL PLUS)</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-05-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">sanofi</Field></Result><Result pos="38"><Field name="sourceId" type="string">1514128</Field><Field name="corporatePublicationTitle" type="string">Efficacy and safety of intensive insulin therapy with insulin glulisine in patients with type 2 diabetes inadequately controlled with basal insulin and oral glucose-lowering drugs (CHANGING)</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-06-20T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Sanofi Aventis</Field></Result><Result pos="39"><Field name="sourceId" type="string">407391</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: insulin like growth factor receptor inhibitors</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-04-27T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Amgen Inc</Field></Result><Result pos="40"><Field name="sourceId" type="string">1386153</Field><Field name="corporatePublicationTitle" type="string">Bioequivalance study of Insulin H Mix 100 IU Suspension</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-02-25T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">SEDICO Co</Field></Result><Result pos="41"><Field name="sourceId" type="string">220172</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: Aztec, heprain (oral), Verex, insulin (oral), Verex</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1996-09-17T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Verex Laboratories Inc</Field></Result><Result pos="42"><Field name="sourceId" type="string">1514957</Field><Field name="corporatePublicationTitle" type="string">Treating Diabetes Using Menin Inhibitors to Regenerate Insulin Producing Beta Cells</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2012-02-15T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Novapeutics LLc</Field></Result><Result pos="43"><Field name="sourceId" type="string">1290723</Field><Field name="corporatePublicationTitle" type="string">APC1 : a novel mechanism for treatment of diabetes type 2 Insulin Replacement Therapy</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2012-05-15T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">TwoToBiotech Ltd</Field></Result><Result pos="44"><Field name="sourceId" type="string">1462312</Field><Field name="corporatePublicationTitle" type="string">Insulin Resistance - A Root Cause of Excess Weight, Obesity and Other Disorders</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-08-06T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Insulite Laboratories</Field></Result><Result pos="45"><Field name="sourceId" type="string">602297</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: BN-006, oral GCSF, oral insulin, Diabetology</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2005-05-12T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Diabetology Ltd</Field></Result><Result pos="46"><Field name="sourceId" type="string">2042984</Field><Field name="corporatePublicationTitle" type="string">Registration of new generic medicines and biosimilar medicines: SEMGLEEE (insulin glargine)</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2018-03-28T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Therapeutic Goods Administration</Field></Result><Result pos="47"><Field name="sourceId" type="string">1308834</Field><Field name="corporatePublicationTitle" type="string">Using A Diabetes Patient's Own Liver Cells As A Novel Source Of Insulin</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2012-06-11T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Orgenesis Inc</Field></Result><Result pos="48"><Field name="sourceId" type="string">1387155</Field><Field name="corporatePublicationTitle" type="string">The announcement of withdrew the clinical trial applications of insulin products</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-02-28T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Dongbao Group</Field></Result><Result pos="49"><Field name="sourceId" type="string">681826</Field><Field name="corporatePublicationTitle" type="string">Pharmacodynamic Properties of VIAject: A Novel Rapid-Acting Regular Human Insulin</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2005-11-30T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Biodel Inc</Field></Result><Result pos="50"><Field name="sourceId" type="string">1994265</Field><Field name="corporatePublicationTitle" type="string">Registration of NCEs: TRESIBA FLEXTOUCH and TRESIBA PENFILL (insulin degludec)</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2017-11-29T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Therapeutic Goods Administration</Field></Result><Result pos="51"><Field name="sourceId" type="string">1519225</Field><Field name="corporatePublicationTitle" type="string">1R43DK100186-01: HEXALOG: A RAPID-ACTING ULTRA-CONCENTRATED INSULIN FORMULATION</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2014-01-29T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Thermalin Diabetes LLC</Field></Result><Result pos="52"><Field name="sourceId" type="string">1896517</Field><Field name="corporatePublicationTitle" type="string">Australian Public Assessment Report for insulin glargine (Edomlus / Lambeto /Toujeo)</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2017-01-23T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Therapeutic Goods Administration</Field></Result><Result pos="53"><Field name="sourceId" type="string">1308836</Field><Field name="corporatePublicationTitle" type="string">Using A Diabetes Patient's Own Liver Cells As A Novel Source Of Insulin</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2012-06-15T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Orgenesis Inc</Field></Result><Result pos="54"><Field name="sourceId" type="string">1465365</Field><Field name="corporatePublicationTitle" type="string">Product Pipeline - Afrezza - A Novel Ultra Rapid-Acting Insulin</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-08-14T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">MannKind Corp</Field></Result><Result pos="55"><Field name="sourceId" type="string">681825</Field><Field name="corporatePublicationTitle" type="string">Pharmacodynamics of VIAject: A Novel Rapid Acting Regular Human Insulin</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2006-06-10T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Biodel Inc</Field></Result><Result pos="56"><Field name="sourceId" type="string">2117833</Field><Field name="corporatePublicationTitle" type="string">Increlex (mecasermin); Recombinant Human Insulin-Like Growth Factor-1</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2018-11-21T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string"></Field></Result><Result pos="57"><Field name="sourceId" type="string">805671</Field><Field name="corporatePublicationTitle" type="string">A Randomised, Double-Blind, Placebo-Controlled Trial of Intranasal Insulin (40IU and 440IU) in Children and Young Adults at Risk of Type 1 Diabetes: Intranasal Insulin Trial II (INIT II)</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2007-01-11T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Royal Melbourne Hospital</Field></Result><Result pos="58"><Field name="sourceId" type="string">1917008</Field><Field name="corporatePublicationTitle" type="string">The announcement about holding subsidiary's withdrawl of launch application for insulin lispro injection and its API</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2016-02-06T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Shanghai Fosun Pharmaceutical (Group) Co Ltd</Field></Result><Result pos="59"><Field name="sourceId" type="string">1550383</Field><Field name="corporatePublicationTitle" type="string">The tolerability and efficacy of oral insulin in Type 2 diabetes patients: A pilotclinical study</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2014-04-24T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Oramed Pharmaceuticals Inc</Field></Result><Result pos="60"><Field name="sourceId" type="string">1697527</Field><Field name="corporatePublicationTitle" type="string">FDA Orphan Drug Designations and Approvals: mecasermin, recombinant human insulin-like growth factor-1; Treatment of Rett Syndrome</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2015-09-21T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Food and Drug Administration</Field></Result><Result pos="61"><Field name="sourceId" type="string">1513868</Field><Field name="corporatePublicationTitle" type="string">Multicenter, open, non-randomised controlled phase IV clinical trial of efficacy and safety for insulin glulisine injected subcutaneously in patients with type 1 diabetes mellitus using also insulin glargine</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2012-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string"></Field></Result><Result pos="62"><Field name="sourceId" type="string">295420</Field><Field name="corporatePublicationTitle" type="string">Cortecs presents phase I oral insulin trial data at Controlled Release Symposium in Stockholm; Cortecs presents phase I oral insulin trial data at Controlled Release Symposium in Stockholm; Planning phase IIa European trial in 3rd quarter</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">1998-08-20T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">PROVALIS Limited</Field></Result><Result pos="63"><Field name="sourceId" type="string">312999</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: Insulin Sensizer, TPO agonists, EPO agonist, Growth Hormone Modulator, Leptin Modulator, Interleukin Modulators, by Receptron</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1999-01-18T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Receptron Inc</Field></Result><Result pos="64"><Field name="sourceId" type="string">1487841</Field><Field name="corporatePublicationTitle" type="string">National Horizon Scanning - Insulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2008-12-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Health Service</Field></Result><Result pos="65"><Field name="sourceId" type="string">231901</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: CADDYS (growth hormone), Emisphere/Lilly, oral insulin, Emisphere, cromolyn, Emisphere, parathyroid hormone, Emisphere</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1997-01-13T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Emisphere Technologies Inc</Field></Result><Result pos="66"><Field name="sourceId" type="string">1649664</Field><Field name="corporatePublicationTitle" type="string">FDA Orphan Drug Designations and Approvals: human insulin (rDNA); Treatment of short bowel syndrome (SBS)</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2015-04-06T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Food and Drug Administration</Field></Result><Result pos="67"><Field name="sourceId" type="string">1080450</Field><Field name="corporatePublicationTitle" type="string">Drug datasheet: Humalog (insulin lispro injection, USP (rDNA origin) 100 units per ml (U-100))</Field><Field name="corporatePublicationType" type="string">Drug Package Insert</Field><Field name="corporatePublicationDatePublication" type="datetime">2010-03-09T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Eli Lilly &amp; Co</Field></Result><Result pos="68"><Field name="sourceId" type="string">2057063</Field><Field name="corporatePublicationTitle" type="string">FDA Orphan Drug Designations and Approvals: Recombinant human insulin receptor monoclonal antibody-N-heparan sulfamidase fusion protein; Treatment of Mucopolysaccharidosis Type IIIA, Sanfilippo A Syndrome</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2018-07-12T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Food and Drug Administration</Field></Result><Result pos="69"><Field name="sourceId" type="string">662540</Field><Field name="corporatePublicationTitle" type="string">National Institute for Health and Clinical Excellence: Inhaled insulin for the treatment of diabetes (types 1 and 2) - Appraisal consultation document</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2006-04-18T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Institute for Health and Clinical Excellence</Field></Result><Result pos="70"><Field name="sourceId" type="string">1134041</Field><Field name="corporatePublicationTitle" type="string">Pharmacokinetics of novel formulations of insulin analogs providing a more rapid onset of action in the diabetic swine model</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2010-09-23T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Biodel Inc</Field></Result><Result pos="71"><Field name="sourceId" type="string">1389168</Field><Field name="corporatePublicationTitle" type="string">FDA Application; Results for Orphan Drug Product Designations Search: recombinant human Naglu- insulin-like growth factor II; Treatment of mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B)</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-03-05T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Food and Drug Administration</Field></Result><Result pos="72"><Field name="sourceId" type="string">1488399</Field><Field name="corporatePublicationTitle" type="string">HTA Report - Short-acting Insulin Analogues for Diabetes Mellitus: Meta-analysis of Clinical Outcomes and Assessment of Cost-effectiveness</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2007-03-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Canadian Agency for Drugs and Technologies in Health (CADTH)</Field></Result><Result pos="73"><Field name="sourceId" type="string">1485180</Field><Field name="corporatePublicationTitle" type="string">NN304-1938: A Multicenter, Open-label, Non-randomized, Non-interventional, Safety study in Patients With Type 2 Diabetes Treated With Insulin Detemir (Levemir)</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2011-10-08T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string"></Field></Result><Result pos="74"><Field name="sourceId" type="string">989576</Field><Field name="corporatePublicationTitle" type="string">Clinical Trial Report: A Multinational, Randomized, Controlled, Open-labeled, Parallel Group Evaluation in Terms of Efficacy and Safety of Metformin 1700 mg/day Plus Twice Daily Biphasic Insulin Aspart 30 or Human NPH-insulin in Subjects with Type 2 Diabetes</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2005-10-19T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Novo Nordisk A/S</Field></Result><Result pos="75"><Field name="sourceId" type="string">583719</Field><Field name="corporatePublicationTitle" type="string">An open label, single arm study to investigate the tolerance, pharmacokinetics and efficacy of a repeated dose of basulin - a new long-acting insulin - in 30 type 1 diabetic patients</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2005-02-08T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Flamel Technologies SA</Field></Result><Result pos="76"><Field name="sourceId" type="string">357450</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: sucralfate, APCls, insulin analogs, NPC-16377, NPC-16570, NPC-18166, adipsin, heparin-EGF-like factor, cell adhesion inhibitors, bradykinin antagonists, KPI-022, BY-2001</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-02-28T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Scios Inc</Field></Result><Result pos="77"><Field name="sourceId" type="string">1383932</Field><Field name="corporatePublicationTitle" type="string">FDA Application;  Results for Orphan Drug Product Designations Search: human insulin beta chain peptide with incomplete Freund's adjuvant vaccine; Treatment of Type 1 diabetes patients with residual beta cell function</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2013-02-11T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Food and Drug Administration</Field></Result><Result pos="78"><Field name="sourceId" type="string">1544426</Field><Field name="corporatePublicationTitle" type="string">A randomized, open-label study of the effect of PEGASYS ® plus COPEGUS® with or without concomitant pioglitazone (Actos®) on early viral kinetics in treatment-naive patients with chronic hepatitis C, genotype-1, and insulin resistance</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2011-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string"></Field></Result><Result pos="79"><Field name="sourceId" type="string">2072992</Field><Field name="corporatePublicationTitle" type="string">Approved determinations and designations for prescription medicines: Orphan drug designation for mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor-1 deficiency (severe primary IGFD)</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2018-07-17T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Therapeutic Goods Administration</Field></Result><Result pos="80"><Field name="sourceId" type="string">1609367</Field><Field name="corporatePublicationTitle" type="string">FDA Orphan Drug Designations and Approvals: human trtravalent, bi-specific monoclonal antibody that binds and co-inhibits two growth factor receptors; insulin-like growth factor receptor 1 (IGF-1R) and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (ErbB3); Treatment of pancreatic cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2014-10-22T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Food and Drug Administration</Field></Result><Result pos="81"><Field name="sourceId" type="string">1971015</Field><Field name="corporatePublicationTitle" type="string">FDA Orphan Drug Designations and Approvals: autologous glioma tumor cells treated with 18-mer oligodeoxynucleotide sequence complementary to insulin-like growth factor type 1 receptor (IGF-1R) codons 2-7 in the IG-1R gene; Treatment of malignant glioma</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2017-10-11T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Food and Drug Administration</Field></Result></PagedResults><DatasetCounts></DatasetCounts><HitTerms><Terms><Term>insulin</Term></Terms></HitTerms></ns2:com.thomson.ls.soa.stack.soaservices.service.contract.soap.v4.search.SearchOutput>